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Pediatric Liver Transplantation 
T.E. Starzl. C. Esquivel, R. Gordon. and S. Todo 
M y ASSIGNED TASK today is to pro-
vide a history of liver transplantation 
in pediatric patients. The history is a rela-
tively brief one, not much more than 25 years 
in duration. The seeds for the liver trials were 
planted in the laboratory in 1958 and 1959, 
with resulting descriptions of the operation 
and of the pathological changes caused by 
rejection. These quite extensive studies were 
completed before chemical immunosuppres-
sion was a reality.I.3 
IMMUNOSUPPRESSION AND KIDNEY 
TRANSPLANTATION 
Such immunosuppression was first tested in 
patients after the far more simple operation of 
renal transplantation. The drugs that were 
used throughout the years included azathio-
prine alone,4 azathioprine plus prednisones to 
which antilymphocyte globulin (ALG) could 
be added as an adjunct,6 and more recently, 
cyclosporine (CsA) alone7 or with steroids8 
and/or monoclonal ALG.9 The most impor-
tant immunosuppressive programs of the last 
25 years are summarized in Table 1. 
In the early 1960s when renal transplanta-
tion was first tried in any numbers, few chil-
dren were included except at our own center at 
the University of Colorado. One of the pedia-
tricians there who had sent us an 8-year-old 
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girl for renal transplantation witnessed so 
much morbidity in his own patient that he 
wrote a thoughtful editorial in the Journal of 
Pediatrics in 1964 that questioned deeply 
whether such endeavors should be allowed to 
go forward. lo One of his principal concerns 
was that with the necessity for long-term 
high-dose steroid therapy (combined with 
azathioprine), normal growth could not be 
expected. As it turned out, Dr Riley's little 
patient is today a practicing physician, and 
many other renal recipients of that era are still 
alive and well. It was not until 5 or 6 years 
later that it was realized that catch-up growth 
in many such children could be expected, 
especially if living related donors had been 
used with the consequent ability to greatly 
reduce steroid therapy for long-term mainte-
nance. ll 
In 1966, the first systematic application of 
renal transplantation in children was de-
scribed in Pediatric Clinics of North Ameri-
ca. 12 In that article, it was noted in a general 
sense that 
the greatest application of whole organ transplanta-
tion may prove to be in the field of pediatric medi-
cine, in which the progression of disease is often due 
to failure of a single organ system. Under these 
circumstances the provision of good renal or hepatic 
or cardiac function might be expected to restore 
normal health. In adult patients comparable prob-
lems are frequently and sometimes unexpectedly 
complicated by disorders other than those to which 
treatment was originally directed. 
The results with renal transplantation were so 
striking that many other centers began similar 
efforts, most notably at the Medical College 
of Virginia where Hume worked. 13 
In the same Pediatric Clinics article, a brief 
notation was made about the possibility of 
liver transplantation as follows: 
It has been natural to think of extending comparable 
replacement therapy to diseases which result in 
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Table 1. The Principal Developments in 
Immunosuppression. Developed With Kidney 
Transplantation and Applied to the Liver 
Agent(s) Year Reference Place 
Azathioprine 1962-1963 4 Boston 
Azathioprine-steroids 1962-1963 5 Denver 
ALG as adjunct 1966 6 Denver 
CsA 1978-1979 7 Cambridge. 
England 
CsA-steroids 1979-1980 8 Denver 
Monoclonal ALG 1980 21 Boston 
functional failure of other organs. At present, liver 
transplantation appears to offer the most immediate 
possibility of clinical utility. Such hope derives prin-
cipally from studies in dogs. 
THE FIRST LIVER TRIALS 
Such optimism might have seemed exces-
sive at that time since seven known clinical 
attempts at liver transplantation had already 
been made, five in Denverl4 and one each 
subsequently in Boston and in Paris, all unsuc-
cessful. However, the basis for hope was 
demonstrable in a large series of dogs given 
nonrelated mongrel livers in 1963 and 1964 
who had survived for more than 4 postopera-
tive months and whose therapy with azathio-
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prine was then stopped. ls A number of these 
dogs lived for long subsequent periods,16 and 
one died of old age more than a decade later. 
On July 23, 1967, a 19-month-old child 
with a large hepatoma was treated with liver 
replacement. Although she died 13 months 
later of metastases from the original malig-
nancy, she provided the first prolonged sur-
vival after orthotopic liver transplantation. 17 
During the next 13 years, many additional 
examples of prolonged survival came from the 
Colorado program l8 and from other centers, 
most notably the Cambridge University and 
Kings College (London) consortium. 19 One of 
our patients from that era is the longest survi-
vor in the world today, more than 17 years 
postoperative. 
However, during any time period between 
1967 and 1980, between three fourths and 
half of all recipients of livers died during the 
first postoperative year. 18 These discouraging 
results were not appreciably improved with 
the acquisition of more experience. The most 
encouraging results were in children who 
throughout the years had a slight survival 
advantage both early and long after trans-
plantation (Fig lA). 
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Fig 1. Total experience 
with orthotopic liver transplan-
tation of 170 patients from 
1t"63 to 1979 (A) and of 720 
patients from 1980 to 1986 (B). 
Note the slight survival advan-
tage of the pediatric recipients 
in both eras. Case accrual in 
the CsA era was until August 
31. 1986. and follow-ups were 
to October 31. 1986. 
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There were a number of reasons for the 
poor results from 1967 through 1979 includ-
ing uncertainty about the best method of 
biliary tract reconstruction, the commission of 
numerous technical errors, the use of livers 
before 1968 and 1969 from donors under 
other than brain death conditions, and the 
tendency to assume without ruling out other 
causes that rejection was always responsible 
for hepatic dysfunction in the posttransplan-
tation period. However, the principal problem 
was that the immunosuppressive regimens 
used up to 1980 had little or no margin of 
safety in the context of liver transplantation. 
THE INFLUENCE OF CsA 
In 1976, Borel and his associates described 
the remarkable new immunosuppressive agent 
CsA.2o The subsequent clinical trials with this 
drug and its eventual marriage with steroids 
in a modern-day, double-drug program had a 
revolutionary effect on liver transplantation. 18 
The one year survival more than doubled 
almost overnight, an advantage which has 
continued for at least the first 5 postoperative 
years (Figure IB). 
Since the introduction of CsA, a further 
refinement in immunosuppression has been 
the clinical use of monoclonal anti-T lympho-
cyte antibodies9,21 manufactured with the 
hybridoma technique of Kohler and Mil-
stein,22 The monoclonal ALGs produced with 
this method are many times more powerful 
than the older polyclonal preparations, and 
they are being used most commonly to reverse 
established rejection.9,21 
TECHNICAL REFINEMENTS 
For children, the most important change in 
technique through the years was the standard-
ization of bile duct reconstruction. In more 
than three fourths of pediatric cases, the 
recipient common duct is absent (biliary atre-
sia) or too small to permit duct-to-duct recon-
struction. Consequently, the most common 
procedure is duct-to-jejunal anastomosis after 
construction of a Roux limb.18 It is astonishing 
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how this simple conclusion required so much 
time for final delineation, but until then one of 
the principal causes of failure was biliary tract 
obstruction or bile fistula formation postoper-
atively. 
During the removal of the diseased native 
liver and the sewing-in of the new organ, 
occlusion of the systemic and splanchnic 
venous circulations can lead to such severe 
venous hypertension that all aspects of the 
operation are in a crisis atmosphere. Decom-
pression of these pools with venovenous bypass 
techniques has made the operation of liver 
transplantation a more easily taught conven-
tional procedure in adults. 18,23,24 
Increasingly, the venovenous bypass tech-
niques have made their way into the pediatric 
hospital. Initially, it was thought that a mini-
mum bypass flow of 1,000 mLjmin would be 
necessary before the heparin-free venovenous 
bypasses would be safe, However, lower-flow 
bypasses have been complication free, and it is 
our present policy to use bypasses for all 
children over 15 kg. 
Today, the most common technical compli-
cations in small recipients are of the vascular 
anastomoses, especially of the artery. Hepatic 
artery thrombosis is second only to rejection 
as a cause for retransplantation in infants. 
THE ORGAN PROCUREMENT PROBLEM 
The multiple-organ procurement tech-
niques developed in the early 1980s have 
become standard worldwide.25 With the origi-
nal technique, meticulous dissection of the 
hepatic hilum was carried out before infusions 
were begun in situ with cold solutions. In a 
more recent modification, the hilar dissection 
has been omitted, and all of the hiIar prepara-
tion is done on the back table.26 Removal of 
the heart, kidneys, and liver can be completed 
in 30 to 60 minutes. 
Pediatric recipients, particularly very small 
ones, still die because of the lack of small 
donors. The possibility of reducing livers from 
larger donors by a partial hepatic resection 
has been extensively examined in the Catholic 
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University of Louvain program by Dr Jean 
Otte. The most common procedure has been 
to remove the lateral segment of the left lobe 
for transplantation and discard the full right 
lobe or more. Although such procedures of 
transplanting partial hepatic remnants have 
been described before, the Belgium team has 
acquired the most extensive and encouraging 
experience. 
It is possible that the criteria for acceptance 
of pediatric donors are too inflexible, with 
consequent wastage of organs. In a recent 
retrospective study of our Pittsburgh cases in 
which donors were thought to be good, bad, or 
poor on the basis of liver function test results, 
blood gas determinations, and cardiocircula-
tory status, there was no correlation between 
the outcome of the recipient and the quality 
classification of the donor.27 Our conclusion 
has been that there is almost no such thing as 
a poor pediatric donor. 
FACTORS IN SURVIVAL 
Throughout the history ofliver transplanta-
tion, a slight (and frequently statistically 
insignificant) advantage has been enjoyed by 
the pediatric recipient (Fig 1). Since 1980, the 
5-year actuarial survival rate of children has 
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been just below 70%, marginally better than 
in adults. Most of the difference was 
accounted for by inclusion in the adult series 
of two diseases, chronic active hepatitis 
caused by B virus and malignant tumors, 
which have a high rate of recurrence after 
transplantation28 (Fig 2). 
In children, there have been no "bad dis-
eases" (Fig 3), and so far, there have been no 
recurrences of original diseases. However, the 
poorest results have been with biliary atresia. 
With biliary atresia, the 5-year survival rate is 
projected at 64%, compared with almost t~n 
percentage points higher than this for the 
other common pediatric diseases (Fig 3). The 
reason is the great difficulty of treating 
patients with biliary atresia after extensive 
prior operations for the performance of por-
toenterostomy or revisions of such proce-
dures. 
The age of the recipient has proved to be the 
single most important prognostic factor in 
pediatric liver transplantation. Our own expe-
rience with recipients of tiny size has been 
somewhat discouraging. Through June 1986 
we have performed transplants on 20 patients 
weighing 5.2 to 9.7 kg.29 The ages of these 
recipients were 3 to 11 months, and all were 
INDICATIONS FOR 720 LIVER TRANSPLANTS 
Fig 2. Diseases in 720 pa-
tients that led to liver replace-
ment during 1980 to 1986. 
Note that malignant tumors 
and chronic active hepatitis 
were not heavily represented 
in the children. These latter 
diagnoses have carried a bad 
posttransplant prognosis in 
adults because of a high rate of 
recurrence of the original dis-
ease. 
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profoundly ill. Otherwise, they would have 
been permitted to grow to a more advan-
tageous size. Eight of the 20 recipients have 
died, including seven deaths in the early post-
operative period and one late death from 
aspiration. Technical problems were frequent. 
Hepatic artery thrombosis occurred in five 
patients, but only one death was related to this 
complication. Three of these patients have 
received retransplants. One patient is stable 
and being allowed to grow before retransplan-
tation will be done. Other technical problems 
included defects of biliary tract reconstruction 
and multiple intestinal perforations from ear-
lier futile portoenterostomies. 
Encouraging as the overall results have 
been, the outlook would be less optimistic by 
about 20% without the frequent application of 
4 5 
Fig 3. Five-year actuarial 
survival rates of pediatric re-
cipients with the most frequent 
diagnoses who were treated in 
the CsAera. 
retransplantation. 18,3o Thus, retransplantation 
has become one of the most common indica-
tions for hepatic replacement. 
SUMMARY 
Liver transplantation, which once was an 
experimental procedure of no practical 'inter-
est, has become the preferred treatment for 
infants and children dying of almost all non-
neoplastic end-stage liver diseases. Liver 
replacement is being provided by many well-
trained teams on all of the continents, as is 
evident from the program today-the first 
international symposium on pediatric liver 
transplantation. I have been honored in giving 
the first paper in the process of introducing 
the remarkable work of a gifted younger gen-
eration of physicians and surgeons. 
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